|
Dr. Brenner joined the company in September of 2006 as Senior Vice President. Dr. Brenner is responsible for the success of the ferumoxytol program, including all aspects of the submission of the New Drug Application for ferumoxytol as an intravenous iron replacement therapeutic for the treatment of anemia in dialysis dependent and non-dialysis dependent chronic kidney disease patients along with the planning and execution of subsequent indications for ferumoxytol. Additionally, Dr. Brenner will be responsible for building the Medical Affairs group at AMAG Pharmaceuticals. Prior to joining AMAG Pharmaceuticals Dr. Brenner worked as Senior Director of Business Development for the Renal and Transplantation Units at Genzyme Corporation. Dr. Brenner received a Bachelors of Science in Biology from Yale University; a Doctor of Medicine from Duke University and a Master in Business Administration from Harvard Business School. Dr. Brenner is Board Certified in Nephrology and Internal Medicine and cares for patients with chronic kidney disease at Brigham and Women's Hospital in Boston. | 